SubHero Banner
Text

Dupixent® (dupilumab) for COPD – New indication approval

September 27, 2024 -  Regeneron and Sanofi announced the approval of a new indication for Dupixent® (dupilumab) for chronic obstructive pulmonary disease COPD).  Dupixent is now approved as add-on maintenance treatment in adults with uncontrolled COPD and an eosinophilic phenotype.

Download PDF